reported on 47 enuretics in a double-blind placebo controlled trial with cross-over: high frequency enuretics were studied while receiving 25 or 50 mg. imipramine according to age. No assessment of wetting frequency was made during a preparatory control period, and the children did not attend the clinic during the treatment period. They found imipramine much superior to placebo. Treatment was continued after the trial period, and 24% of their subjects were ultimately cured after gradual withdrawal of the drug.
The period of observation after stopping treatment extended to 3 months. It was suggested that the response was dose dependant, and that gradual withdrawal led to a better result than sudden withdrawal. No description of incidence of emotional disturbance or of family history was given for their population.
Our study has been designed to test whether or not these authors' findings could be repeated in a population fairly typical of that seen in an English Local Authority enuretic clinic.
We have, in addition, extended the period of follow-up study, and have included in the design of our trial a no-treatment control period.
Observations have been made on the physical environments and psychiatric status of the patients and their relatives.
Material and Method
The subjects were taken from children referred to a Local Authority enuretic clinic which is run in the paediatric department of University College Hospital. Any child of school age with a history of noctumal enuresis more than twice a week was provisionally accepted for the trial.
to keep a record of the bed-wetting, and this was discussed at the second visit, a fortnight later, when a second sample of urine was collected and other investigations arranged if indicated. Thereafter each child attended the clinic at fortnightly intervals. At the third visit, if investigations revealed no disease or abnormality of the urinary tract, and record keeping confirmed that the bed was wet three or more times in a fortnight, the child was admitted to the trial. It is interesting to note that of 75 patients for whom the pre-trial month records were completed, only 5 had more wet nights, and 10 the same, as the mother reported. The remainder all 'improved' substantially, by an over-all average of 5-4 dry nights/month. Those reported as having between 4 and 8 dry nights improved the most, by up to 18 nights.
If treatment was needed it was then explained that the child would be receiving tablets which would vary in content (and would sometimes be inactive) according to a predetermined schedule, in order that the effect of the drug might be studied.
In all, 81 consecutive referrals were considered for the trial, of whom 33 were referred by school medical officers, 31 by general practitioners, and 17 from other clinics in the hospital. There was no significant difference between these three groups in age, sex, or emotional disturbance (Table I) . 30 had previously been dry for at least a month. The remainder had had no dry periods for more than a few days.
Physical examination showed no relevant abnormality, though there were various incidental findings, e.g. squints, obesity, and non-significant cardiac murmurs. Urinary symptoms other than enuresis were present in 10 children, but none of these had any significant abnormality on examination of the urine. Urine examination was abnormal in 21 children (Table II) .
Four children had significant bacilluria. None of these had albuminuria, but 3 had pyuria. Cell counts in the other were normal. 2 had an abnormal intravenous pyelogram, and one, the only boy of the 4, had unilateral pelvi-ureteric obstruction with hydronephrosis.
There was no increased frequency of daytime wetting or secondary enuresis amongst the 22 with any abnormality of the urine. The trend, though not statistically significant, is for there to be fewer urine abnormalities amongst the secondary enuretics.
We considered 26 of the children to be psychologically disturbed. Among these were 14 whose parents had expressed concern at their child's behaviour, and a further 12 whose parents had made no complaint.
There were no mentally handicapped children, and none in institutional care. School reports were obtained whenever possible, and of the 70 for whom we had information, 24 were thought by their teacher to be working below their full potential, and 17 were considered to be disturbed in behaviour. The teachers' assessment of disturbance agreed more closely with ours than with the parents' assessment.
The occupations of the fathers were mixed, though, as can be seen from Table III , there was a preponderance were apart. 17 parents had either suffered from overt psychiatric illness or were considered to show it when seen at the clinic.
A family history of enuresis was obtained in 51 cases (Table IV) . The type and degree of enuresis are often considered to be relevant to prognosis. 29 children were still wet by day occasionally. Daytime wetting was, as might be expected, most frequent under the age of 8 (18 cases), and girls were more often affected than boys (16 cases). 30 were said to have had a month or more of consecutive wet nights, and in the month before attending only 7 were said to have had more than 14 dry nights.
Eleven children had associated faecal soiling, defined as significant soiling of the pants with faecal material more than once in the last year.
Though none of these factors necessarily had any bearing on the aetiology of the enuresis, they clearly are relevant to any appraisal of the results of the treatment.
Trial Procedure Dosage was calculated on the basis of surface area, using the percentage method (Butler and Richie, 1960) (Table V) .
Two dosage schedules were used, based on maximum doses of 75 mg. (high) and 50 mg. (low), respectively. Active drug and a placebo were used in a double crossover design with 9 treatment groups, and each strength or placebo was dispensed in uniform packs of 16 white tablets. (This ensured that tablets were returned, as an extra check on consumption.) In practice, use of the lower range usually means giving a dose of 25 mg. between the ages of 4 and 7, 35 mg. between 8 and 11, and 50 mg. over 11.
Patients were allocated by a stratified randomization consisting of sets of Latin squares, catering for age, sex, and previous psychiatric treatment, which in the absence of any better criterion was used as an operational definition of emotional disturbance. This randomization was superimposed on the 9 treatment combinations to ensure, so far as possible, that there was an even distribution of treatments within each group of children of similar age, sex, and psychiatric status.
The allocation to treatment group was not known by any of the clinic staff seeing the child.
At the end of the third month of treatment, each treatment was split in two. Half the patients stopped treatment abruptly, the rest having a gradually reduced dosage over a four-week period. This was also done according to a pre-arranged random plan. After the drug was stopped each child was asked to keep a record for a further month, and during this time no further treatment was given. At the end of this month further treatment, either by drugs or by the alarm as indicated, was given if necessary, but this did not count as part of the trial.
Results
Of 81 subjects who were considered for the trial, 14 were excluded because of urinary infection or improvement before treatment and 5 others stopped attending before treatment was started. Of the 62 who entered the trial, 3 gave no results, 1 being too unreliable in taking tablets and reporting, and 2 lapsing soon after the start of treatment. This left 59 subjects for analysis. Of the other 3 who entered the trial, 1 started on a high dose and 2 on placebo.
The figures analysed consisted of a score, representing the number of dry nights out of 28, for each of 4 periods: Period 1, before treatment; Period 2, first treatment; Period 3, second treatment; Period 4, third treatment (usually first treatment repeated).
In some cases the number of nights observed within a period was less than, or more than, 28. In such cases the score was calculated as the number of dry nights multiplied by 28 and divided by the number of nights observed.
Within subjects analysis, imipramine versus placebo. 17 subjects had a treatment scheme in Periods 2, 3, and 4 following one of the 3 patterns: Placebo, Low, Placebo; Placebo, High, Placebo; Low, Placebo, Low.
If the drug has a useful effect, we should expect Period 3 to show a higher score than either Period 2, or Period 4 in either of the first two patterns; Period 3 to show a lower score than either Period 2 or Period 4 in either of the last two.
Of the 17 subjects, 15 did in fact show this result, the score either going up and then down again for Placebo, Drug, Placebo or going down and then up again for Drug, Placebo, Drug. Of the other 2 subjects, one showed no effect at all, the score remaining constant for all three periods, while the other showed the reverse of the expected effect, going up and then down again for Drug, Placebo, Drug.
The result is so clear cut that a test of significance is unnecessary. If a probability is required, it may be noted that if the drug had no effect, then we should expect half the results to favour the drug, and half to favour the placebo in the long run (ignoring results that show no difference). In this case, the probability of 15 results going one way and only one the other is 0 0005 or 1 chance in 2000. There can, therefore, be little doubt that imipramine has a genuine effect. The results are shown in Table VI and are seen to be completely symmetrical. There is no evidence whatever, from this analysis, that the high dose is more effective than the low.
Between subjects analysis. In the between subjects analysis, an approximation to Wilcoxon's test (Wilcoxon, 1945) was used for calculating probabilities, two-tailed probabilities being used Table VIII Only Period 4 shows any statistically significant differences here, both doses doing better than placebo. In Periods 2 and 3 also the differences are in the expected direction (though Table VIII does not show this). There is no significant difference between high and low doses.
For Period 2, what difference there is, is in the direction of high doing better than low, but in Period 3 the sign of the difference is reversed. In Period 4 the observed difference is so small that chance alone would usually produce a greater discrepancy.
A further analysis to test the effect of different doses can be made by comparing the differences between Period 1 and Periods 2, 3, and 4. This gets rid of some of the differences between subjects and thus makes the test more sensitive. When this is done there is still no significant difference between the effects of high and low doses. Because it seemed possible that initial age and sex differences An interim analysis, 9 months after the start of the trial, revealed a significant drug effect. On the basis of this finding, we decided it was unethical to continue to use placebo, or to allow patients who had only been given placebo to go through a further month without effective treatment.
Because of these and other losses only 32 patients were observed for a month without any treatment after Period 4.
The results of this group showed no significant differences between the scores of those suddenly withdrawn from the drug, and those gradually withdrawn. The design of the trial made it possible for patients to have had continuous treatment for from 4 to 16 weeks. The length of continuous treatment before withdrawal made no significant difference to the score.
On the other hand there was a significant relation between the total quantity of drug received, and improved scores after withdrawal (p = 0 03).
Side-effects. Before starting the trial, parents were warned that their children might experience such minor effects as constipation, and dry mouth. In fact only 5 patients reported these side-effects, and 3 of them were receiving placebo at the time that the symptom was complained of.
The most important side-effect, which was reported in 3 patients in the population under study, but which has been seen in a further 3 patients in this clinic, was an alteration in mental state. The child became restless and irritable, tearful and fidgety, found it difficult to concentrate, and did worse at school. There was also a disturbance in sleep, with nightmares, restlessness at night, and difficulty in going to sleep. Sleep disturbances without more widespread behaviour disturbances were reported in a further 3 patients. Follow-up studies. Of the 59 who entered the trial, follow-up data were obtained from 52, usually during continued attendance, but in a few cases by correspondence. Follow-up ranged from 3 to 14 months, and 36 children were followed for over 6 months.
The disposal of patients at the time of writing is given in Table X. Active social work (home visits, help with housing problems, and liaison with other social agencies) was carried out with 18 families. 8 parents were thought to need treatment for their mental state, and this was arranged through the general practitioner, or the hospital psychiatric department.
Treatment at the end of the double-blind trial was decided upon by the use of simple clinical criteria. When a patient had responded to imipramine during the double-blind period this drug was given another try. When the patient had only received placebo a trial of imipramine also was used.
The children who had only received imipramine in the low dose range were usually given a larger At some stage during their attendance at the clinic 56 patients were given imipramine. Of these, 48 improved, 5 were unchanged, and 3 wet more frequently while taking the drug. Amongst the 56 who at some time took imipramine, 20 became dry while on the drug for 14 or more consecutive nights. But of this subgroup only 3 were known to have remained dry after the drug was withdrawn. At the time of writing, 2 of these remain dry, without any treatment at all, for 6 and 11 weeks. One other child relapsed 9 weeks after the drug was withdrawn. There was one other child who had been dry for more than 14 days while on the drug, but he stopped attending when the drug was withdrawn. More responders were children under 9 (X2 with Yates' correction = 6-59, p = 0 0015), and 'secondary' enuretics (X2 = 4 489, p = 0 017). There were 3 girls and 1 boy in the sample who had urinary infections, a higher incidence than would be expected from the population at large (Kunin, Zacha, and Paquin, 1962) . None of these complained of specific urinary symptoms; all had complained of abdominal pain, but so had many other non-infected children. None had albuminuria, though many patients who had transitory albuminuria had no urinary infection. Routine urine microscopical and bacteriological screening for all patients presenting with enuresis is important.
Routine testing for albuminuria does not seem to be of any value. It also appears from our findings that diurnal incontinence, which paediatricians commonly believe to merit particular investigation, is not necessarily associated with urinary tract abnormality or infection, and does not by itself justify full uroradiological screening.
Of 67 who accepted treatment in this series, 21 recovered; 17 more are still attending. The proportion who stopped attending while having drug treatment is only 13 5%, and compares favourably with the lapse rate for the alarm of 29 5% (Young and Turner, 1965) This trial could not have been conducted without the generous help of Geigy (U.K.) Ltd., and in particular of Dr. Cyril Maxwell.
